Daewoong Pharmaceutical Presents Baseline Characteristics of 104 Patients in Global Phase 2 Trial for IPF Drug Candidate 'Bersiporocin' at ERS 2026
Why now
Thesis: Early-stage drug progress, distant catalyst
Catalyst to watch: Top-line Phase 2 data in H1 2027
Main risk: Trial failure or delay possible
Why it matters
Phase 2 IPF trial progress matters for Daewoong, but top-line data is not due until H1 2027.
Details
104 IPF patients enrolled in US and South Korea as global Phase 2 trial progresses toward completion Study includes both antifibrotic-treated and untreated patients; top-line data expected in H1 2027 First-in-class PRS inhibitor being developed as a potential new therapeutic option for...
Related assets & topics
HealthcareSources
- prnewswire · 2026-09-24 07:00 UTC